Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program
NCT05140421 · View on ClinicalTrials.gov ↗
Study Summary
The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions. As RWHAP serves \>50% of US PWH, RWHAP outcomes are vital to achieving "getting-to-zero"/ Ending the HIV Epidemic (EHE) Plan targets. As a grantee for RWHAP Part A (RWPA) funding distributed to the counties/cities severely affected by HIV, New York City (NYC) conducts regular HIV care continuum monitoring citywide and in its RWPA programs, which offer support services to reduce social and behavioral barriers to care/treatment. Local data consistently show lower viral suppression (VS) among RWPA clients in HIV care than among non-RWPA PWH in HIV care. Relative to NYC HIV cases overall, NYC RWPA clients (\~14,000 per year) over-represent Black and Latinx PWH and high-poverty neighborhoods. To address local outcome disparities and to fill gaps left by data-to-care strategies and research focused on medical care (re-)linkage, the investigators propose to implement and rigorously evaluate the effectiveness of a novel 'data-to-suppression' (D2S) intervention among RWPA behavioral health and housing program clients who are in HIV care but unsuppressed. Surveillance-based reports on unsuppressed clients plus D2S capacity-building assistance will guide RWPA providers in targeting and delivering evidence-informed strategies to improve VS.
Conditions Studied
Interventions
- OTHER Data to Suppression (D2S)
- OTHER Usual practice
Study Locations (20)
New York
- Alliance for Positive Change — New York
- Mount Sinai Beth Israel — New York
- Exponents, Inc. — New York
- GMHC — New York
- African Services Committee, Inc. — New York
- Harlem United — New York
- New York Presbyterian Hospital — New York
- Bailey House, Inc. — New York
- New York Harm Reduction Educators, Inc. — New York
- The Institute for Family Health — New York
- NYC Health and Hospitals Harlem — New York
- Project Hospitality, Inc. — New York
- Boom!Health — New York
- BronxWorks, Inc. — New York
- St. Ann's Corner of Harm Reduction — New York
- Tolentine Zeiser Community Life Center — New York
- Housing Works — New York
- Research Foundation of State University of New York — New York
- La Nueva Esperanza, Inc. — New York
- NYC Health and Hospitals Woodhull — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,494 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05140421
The ClinicalTrials.gov registry entry for NCT05140421 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City University of New York, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hiv appearing as the primary indexed condition, and to 2 interventions — of which Data to Suppression (D2S) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05140421 reports 20 study locations spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05140421 about?
NCT05140421 is a clinical study titled "Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program". The Ryan White HIV/AIDS Program (RWHAP) for low-income people with HIV (PWH) is a key resource for reducing HIV health disparities and scaling up evidence-based interventions. As RWHAP serves \>50% of US PWH, RWHAP outcomes are vital to achieving "getting-to-zero"/ Ending the HIV Epidemic (EHE) Plan...
What is the current status of trial NCT05140421?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,494 participants. The study started on 2021-12-15. Estimated completion is 2026-04-30.
What conditions does trial NCT05140421 study?
This clinical trial studies the following conditions: Hiv. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05140421?
The interventions under investigation include: Data to Suppression (D2S) (OTHER), Usual practice (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05140421?
This trial is sponsored by City University of New York, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05140421 being conducted?
This trial has 20 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.